Key Takeaways
- Eli Lilly’s lepodisiran significantly reduced lipoprotein(a) levels by nearly 94% in clinical trials.
- This medication could benefit the 1.4 billion people worldwide at risk due to elevated Lp(a) levels.
- No serious adverse events were reported during trials, indicating a promising safety profile.
Breakthrough in Lp(a) Treatment
Eli Lilly’s experimental drug, lepodisiran, has shown exceptional promise in recent clinical trials by dramatically lowering lipoprotein(a) (Lp(a)) levels by nearly 94%. This genetic risk factor for heart disease is prevalent among approximately 1.4 billion people globally who have elevated Lp(a) levels, which can increase the likelihood of heart attack, stroke, and other cardiovascular conditions.
The results from a mid-stage trial were presented at the American College of Cardiology conference in Chicago and also published in the New England Journal of Medicine. The trial involved 210 participants—141 received lepodisiran at doses of one or two 400 mg while 69 were given a placebo. Participants who were treated maintained significantly reduced Lp(a) levels over a six-month period.
Dr. Steven Nissen, a cardiologist from the Cleveland Clinic and the study’s author, emphasized the advantage of the drug’s infrequent dosing regimen. He remarked, “What we have is a drug that can lower lipoprotein(a) with very infrequent administration,” representing a potential shift in how Lp(a) could be managed.
Currently, there are no approved treatments for managing Lp(a), unlike LDL cholesterol, which can be controlled through lifestyle changes and statins. Many individuals remain unaware of their high Lp(a) levels, which pose serious risks, particularly affecting those of African descent.
In light of these promising results, Lilly is advancing lepodisiran into Phase 3 clinical trials. A second Phase 3 trial is in progress to assess whether the reduction of Lp(a) correlates with fewer cardiovascular incidents, with enrollment expected to conclude later this year.
The pursuit of effective treatments for Lp(a) is gaining momentum; other pharmaceutical companies are also competing, including Silence Therapeutics with their drug zerlasiran, Amgen with olpasiran, and Novartis with pelacarsen. Additionally, Lilly is working on muvalaplin, which is currently the only oral treatment for elevated Lp(a) in clinical trials.
Importantly, the trial results for lepodisiran revealed no serious adverse events, signaling a favorable safety profile, which, combined with its high efficacy, makes it a significant development in cardiovascular health management.
The content above is a summary. For more details, see the source article.